Clinical Trial

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The investigators' goal is to show that in hypertensive men and women with left ventricular hypertrophy (LVH) treatment with a mineralocorticoid receptor (MR) antagonist, versus a thiazide-like diuretic, will improve coronary microvascular function and cardiac efficiency, which will associate with improvements in LV structure and function. The investigators will achieve this through a randomized, controlled, basic experimental study involving humans (BESH).
Protocol Amendment History 1 change
notable Primary completion pushed: 2027-01-01 -> 2027-04-01 2026-04-07
Trial Details
NCT Number NCT05593055
Lead Sponsor Brigham and Women's Hospital
Conditions Hypertension, Left Ventricular Hypertrophy
Enrollment 75 participants
Start Date 2023-08-25
Primary Completion 2027-04-01 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-06